An artisanal law firm based in beautiful Port Townsend. Created by attorney and law professor, Denis Stearns, to provide real-world solutions to a wide range of challenges on behalf of businesses, non-profit organizations, and injured persons.

All in Regulatory Compliance

Oct 26

Oct 26 FDA Issues Draft Guidance Document for Produce Safety Rules

Denis Stearns

Regulatory Compliance, Food, FDA, FSMA, FDA Produce Safety Rules

Jan 19
Jan 19 FDA ENFORCEMENT ACTIONS AGAINST INDIVIDUAL RESTAURANTS: Might the FDA’s Reach Exceed Its Grasp? Part II

Denis Stearns

Regulatory Compliance, Restaurants, Regulations, Food Business, Food

Jan 12
Jan 12 FDA ENFORCEMENT ACTIONS AGAINST INDIVIDUAL RESTAURANTS: Might the FDA’s Reach Exceed Its Grasp? Part I

Denis Stearns

Regulations, Food, Regulatory Compliance, Food Business, Restaurants

Apr 27

Apr 27 USDA, SALMONELLA, AND THE COWARDLY LION: A PROFILE IN THE LACK OF COURAGE

Denis Stearns

USDA, Regulatory Compliance, meat inspection, Regulations

Oct 26 FDA Issues Draft Guidance Document for Produce Safety Rules

Jan 19
Jan 19 FDA ENFORCEMENT ACTIONS AGAINST INDIVIDUAL RESTAURANTS: Might the FDA’s Reach Exceed Its Grasp? Part II

Jan 12
Jan 12 FDA ENFORCEMENT ACTIONS AGAINST INDIVIDUAL RESTAURANTS: Might the FDA’s Reach Exceed Its Grasp? Part I

Apr 27 USDA, SALMONELLA, AND THE COWARDLY LION: A PROFILE IN THE LACK OF COURAGE

Stearns Law, PLLC

211 Taylor Street, Suite 5

P.O. Box 2027

Port Townsend, WA 98368

Phone: 360-379-2415

Email: Denis@Artisanal-Law-Firm.com

OR ~ Denis@StearnsLawPLLC.com

Let’s talk!
Your first consultation is free.

Jan 19 Jan 19 FDA ENFORCEMENT ACTIONS AGAINST INDIVIDUAL RESTAURANTS: Might the FDA’s Reach Exceed Its Grasp? Part II

Jan 12 Jan 12 FDA ENFORCEMENT ACTIONS AGAINST INDIVIDUAL RESTAURANTS: Might the FDA’s Reach Exceed Its Grasp? Part I

Jan 19
Jan 19 FDA ENFORCEMENT ACTIONS AGAINST INDIVIDUAL RESTAURANTS: Might the FDA’s Reach Exceed Its Grasp? Part II

Jan 12
Jan 12 FDA ENFORCEMENT ACTIONS AGAINST INDIVIDUAL RESTAURANTS: Might the FDA’s Reach Exceed Its Grasp? Part I